It didn’t take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been
It didnt take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been named president of ultrafast CT developer Imatron of South San Francisco, CA. He has served as an Imatron board member for 12 years.
Ross is the second Cemax-Icon executive to leave the company in recent months. Former vice president of sales and marketing Oran Muduroglu left the company in 1998 to head up Stentor, a San Francisco startup formed to commercialize dynamic transfer syntax (DTS), a protocol for low-cost enterprise-wide image distribution developed by a University of Pittsburgh Medical Center PACS research team. A DTS demonstration drew much attention in the infoRAD exhibit area at last years RSNA meeting.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.